



# THE BRITISH JOURNAL OF PSYCHIATRY

November 1996

Vol. 169

## Editorials

First-rank symptoms or rank-and-file symptoms?

*P. Crichton* 537

Commentaries on 'First-rank symptoms or rank-and-file symptoms?'. *W. T. Carpenter Jr., P. McGuffin, C. S. Mellor, E. Fuller Torrey, J. O'Grady, J. R. Geddes, G. Christofi, D. L. Sackett,*

*J. Wing, H. Häfner and T. J. Crow* 541

An approach to planning services for bulimia nervosa. *J. L. Treasure, N. A. Troop and A. Ward*

551

## Review Articles

Aspects of perinatal psychiatric illness. *D. B. Pritchard and B. Harris*

555

Psychotherapy integration: its implications for psychiatry. *A. Albeniz and J. Holmes*

563

## Papers

Eye movement desensitisation treatment utilises the positive visceral element of the investigatory reflex to inhibit the memories of post-traumatic stress disorder: a theoretical analysis. *M. J. MacCulloch and P. Feldman*

571

The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISOs) coordinated by the World Health Organization. *P. Mason, G. Harrison, C. Glazebrook, I. Medley and T. Croudace*

580

First-contact incidence rates of schizophrenia in Trinidad and one-year follow-up. *D. Bhugra,*

*M. Hilwig, B. Hossein, H. Marceau, J. Neehall, J. Leff, R. Mallett and G. Der* 587

Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on psychotic symptoms. *V. Drury, M. Birchwood, R. Cochrane and F. Macmillan* 593

Cognitive therapy and recovery from acute psychosis: a controlled trial. II. Impact on recovery time. *V. Drury, M. Birchwood, R. Cochrane and F. Macmillan* 602

Peer review of 'Cognitive therapy and recovery from acute psychosis'. *D. A. W. Johnson* 608

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. *U. Heresco-Levy, D. C. Javitt, M. Ermilov, C. Mordel, A. Horowitz and D. Kelly* 610

Large variations of plasma levels during maintenance treatment with depot neuroleptics. *E. Tuninger and S. Levander* 618

Emotional overinvolvement in parents of patients with schizophrenia or related psychosis: demographic and clinical predictors. *H. Bentsen, B. Boye, O. G. Munkvold, T. H. Notland, A. B. Lersbryggen, K. H. Oskarsson, I. Ulstein, G. Uren, H. Bjorge, R. Berg-Larsen, O. Lingjaerde and U. F. Malt* 622

Caudate nucleus morphology in tardive dyskinesia. *K. W. Brown, T. White, J. M. Wardlaw, N. Walker and D. Foley* 631


*continued p. ii*

Published by The Royal College of Psychiatrists

ISSN 0007-1250

# Now you can lift depression with the body in mind

Site-specific 'Cipramil' addresses four key dimensions of antidepressant therapy:



**Cipramil**  
citalopram

Specifically treating depression

**Abbreviated Prescribing Information**

**Presentation:** 'Cipramil' tablets. PL 0458/0058, each containing 20mg of citalopram as the hydrobromide. 28 (OP) 20mg tablets £21.28.

**Indications:** Treatment of depressive illness in the initial phase and as maintenance against relapse/recurrence. **Dosage:** Adults. 20mg a day. Depending upon individual patient response, this may be increased in 20mg increments to a maximum of 60mg. Tablets should not be chewed, and should be taken as a single oral daily dose, in the morning or evening without regard for food. Elderly. 20mg a day increasing to a maximum of 40mg dependent upon individual patient response. Children. Not recommended. Restrict dosage to lower end of range in hepatic impairment. Dosage adjustment not necessary in cases of mild/moderate renal impairment. No information available in severe renal impairment (creatinine clearance <20ml/min). **Contra-indications:** Combined use of 5-HT agonists. Hypersensitivity to citalopram. **Pregnancy and Lactation:** Safety during human pregnancy and lactation has not been established. Use only if potential benefit outweighs possible risk. **Precautions:** Driving and operating machinery. History of mania. Caution in patients at risk of cardiac arrhythmias. Do not use with or within 14 days of MAO inhibitors: leave a seven day gap before starting MAO inhibitor treatment. **Drug Interactions:** MAO inhibitors (see Precautions). Use lithium and

tryptophan with caution. Routine monitoring of lithium levels need not be adjusted. Alcohol is not advised. **Adverse Events:** Most commonly nausea, sweating, tremor, somnolence and dry mouth. **Overdosage:** Symptoms have included somnolence, coma, sinus tachycardia, occasional nodal rhythm, episode of grand mal convulsion, nausea, vomiting, sweating and hyperventilation. No specific antidote. Treatment is symptomatic and supportive. Early gastric lavage suggested. **Legal Category:** POM 24.1.95. Further information available upon request. Product licence holder: Lundbeck Ltd, Sunningdale House, Caldecotte Lake Business Park, Caldecotte, Milton Keynes, MK7 8LF. 'Cipramil' is a trademark. © 1995 Lundbeck Ltd.

Date of preparation: May 1995

**References**

1. Hyttel J. XXII Nordiske Psykiater-Kongres, Reykjavik, 11 August, 1988: 11-21.
2. Eison AS et al. Psychopharmacology Bull 1990; 26 (3): 311-315.
3. Rosenberg C et al. Int Clin Psychopharmacol 1994; 9 (Suppl 1): 41-48.
4. Shaw DM et al. Br J Psychiatry 1986; 149: 515-517.
5. Bech P and Caldwell P. Int Clin Psychopharmacol 1992; 6 (Suppl 5): 45-54.
6. Sindrup SH et al. Ther Drug Monit 1993; 15: 11-17.
7. Van Harten I. Clin Pharmacokinet 1993; 24 (3): 203-220.

**Lundbeck**  
Research for a better life

**The Hester Adrian Research Centre  
and the Institute of Psychiatry**

announce the publication of the long awaited

**PAS - ADD**

*Psychiatric Assessment Schedule for Adults with Developmental Disabilities*

The most comprehensive Axis I diagnostic system for learning disability psychiatry.

- Semi-structured clinical interview for use with patients and informants.
- Flexible format for use across a wide range of intellectual ability.
- Derived from SCAN.
- Uses the SCAN clinical glossary.
- Gives ICD 10 diagnoses via computer algorithm.

Supplied complete with  
Supplementary Glossary : 30 Score Forms : Floppy disk

Price: £145 incl. VAT and p&p.

Orders and enquiries to: Jackie Hales, Hester Adrian Research Centre,  
University of Manchester, Manchester M13 9PL. Fax: 0161 275 3333;  
e-mail: [jackie.hales@man.ac.uk](mailto:jackie.hales@man.ac.uk)

Accompanying cheques should be made payable to **University of Manchester**.

# Psychotherapy Prize

The Psychotherapy Section of the Royal College of Psychiatrists is offering a prize of £500 for a paper relevant to psychotherapy as practised within the field of psychiatry. This may be in any area or discipline in psychotherapy: e.g. psychodynamic, systems-based or behavioural-cognitive psychotherapy.

The winning paper, if not already published, will be considered for publication in the *British Journal of Psychiatry*. Other high-quality entries may also be published.

Entries should be submitted by 31 March 1997 to: The Psychotherapy Prize, Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London, SW1X 8PG.

## *Psychiatry in New Zealand*

On behalf of New Zealand client hospitals, we are seeking applications for the following full time posts:

**Head, Department of Psychiatry  
Consultant - Adult acute**

**Consultant - Child, Adolescent and Family  
Consultant - Community Mental Health Service  
Registrars (posts commence in Nov 96)**

also, 6 and 12 month Locum posts in **Community Mental Health**.

Posts are available in both Islands, registration, immigration and relocation assistance may be provided. Recent changes to New Zealand's Medical Registration procedures will be discussed with appointable candidates.

Please fax curriculum vitae to:

**New Zealand Medical Staffing Ltd,  
fax +64-9-630 9622, ph +64-9-630 1769,  
PO Box 74385 Market Road, Auckland,  
New Zealand.**

New Zealand Medical Staffing Ltd is a subsidiary of HealthLink New Zealand Group; New Zealand's largest provider of personnel to the Health Sector.

## **DIRECT MEDICAL APPOINTMENTS**

We have a **LOCUM** position for you.

Long or Short term

All areas of the UK covered

**EXCELLENT RATES.** Professional Service  
All documentation arranged including visas

## **WEEKLY INCENTIVE SCHEME OVERSEAS HOLIDAYS, FLIGHTS, WEEKEND BREAKS**

Permanent and Substantive positions  
also available

Call DMA Now Tel 01792 472525 or  
Fax 01792 472535

24 hr service

**International Review of Psychiatry  
Volume 2**

Edited by Felice Lieh-Mak, MD  
& Carol C. Nadelson, MD  
Aug 1996 494pp  
0-88048-992-8 Hardback £55.95

**ICD-10 Casebook: The Many Faces of  
Mental Disorders  
Adult Case Histories According to  
ICD-10**

T.B. Üstün et al  
Aug 1996 266pp  
0-88048-989-8 Hardback £28.50

**The Spectrum of Factitious Disorders**

Edited by Marc D. Feldman, MD  
& Stuart J. Eisendrath, MD  
Aug 1996 257pp  
0-88048-909-X Hardback £28.95

**Concise Guide to Assessment and  
Management of Violent Patients  
Second Edition**

Kenneth Tardiff, MD, MPH  
Sep 1996 320pp  
0-88048-344-X Paperback £16.95

**The Psychiatry of Stroke**

D. Peter Birkett, MD  
Sep 1996 472pp  
0-88048-540-X Hardback £43.50

**Posttraumatic Stress Disorder  
Acute and Long-Term Responses to  
Trauma and Disaster**

Edited by Carol S. Fullerton, PhD  
& Robert J. Ursano, MD  
Oct 1996 344pp  
0-88048-751-8 Hardback £31.95

**Electronic DSM-IV Version 2.0 Plus  
Practice Guidelines of the American  
Psychiatric Association**

American Psychiatric Association  
Oct 1996  
0-88048-788-7 CD-ROM £103.95

**Structured Clinical Interview for  
DSM-IV Axis I Disorders**

**Clinician Version**  
Michael B. First, MD et al  
Nov 1996

**User's Guide**

160pp 0-88048-931-6 Paperback Price TBA

**Administration Booklet**

96pp 0-88048-932-4 Spiral bound Price TBA

**Scoresheet: Set of Five**

64pp 0-88048-933-2 Paperback Price TBA

**Obsessive-Compulsive Disorder  
Spectrum**

**Pathogenesis, Diagnosis, and  
Treatment**

Edited by Jose A. Yaryura-Tobias, MD, FACP  
& Fugen A. Neziroglu, PhD  
Nov 1996 528pp  
0-88048-707-0 Hardback £54.95

**The Selfish Brain  
Learning from Addiction**

Robert L. DuPont, MD  
Nov 1996 624pp  
0-88048-686-4 Hardback £23.95

**The Dilemma of Ritual Abuse  
Cautions and Guides for Therapists**

Edited by George A. Fraser, MD, FRCPC  
Dec 1996 276pp  
0-88048-478-0 Hardback £30.95

**Manual of Clinical  
Psychopharmacology  
Third Edition**

Alan F. Schatzberg, MD et al  
Dec 1996 446pp  
0-88048-921-9 Spiral bound £37.95

**Psychotropic Drug Handbook  
Seventh Edition**

Paul J. Perry, PhD et al  
Dec 1996 616pp  
0-88048-851-4 Spiral bound £33.95

*For further information on these and any other APP titles, please contact our European office :*  
3 Henrietta Street, Covent Garden, London WC2E 8LU, UK  
Tel : 0171 240 0856 Fax : 0171 379 0609

# REASON TO BE CHEERFUL



**LUSTRAL™ 50mg**

sertraline



**Established in treating depression**



**Abbreviated Prescribing Information:**  
**LUSTRAL™ (sertraline) Presentation:** Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness and accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes including accompanying symptoms of anxiety.

**Dosage:** LUSTRAL should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if appropriate, to 150mg or a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contra-indications:**

Hypersensitivity to LUSTRAL. Hepatic insufficiency. **Use during pregnancy:** LUSTRAL should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. LUSTRAL should be discontinued in a patient who develops seizures. LUSTRAL should not be administered to patients concurrently being treated with tranquilizers who drive or operate machinery. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of LUSTRAL. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug interactions:** Administer with caution in combination with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with LUSTRAL. It is recommended that plasma lithium levels be monitored following initiation of LUSTRAL. Although LUSTRAL has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. The potential for LUSTRAL to interact with other highly protein bound drugs should be borne

in mind. The potential of LUSTRAL to interact with e.g. warfarin, diazepam, tolbutamide and cimetidine has not been fully assessed. With warfarin prothrombin time should be monitored when LUSTRAL is initiated or stopped. **Side-effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dyspepsia, dizziness, insomnia and somnolence. Asymptomatic elevations in serum transaminases have been reported infrequently (approx. 0.8%) in association with LUSTRAL. These usually occurred within the first 9 weeks treatment and resolved on cessation of therapy. Malaise and rash have been reported. Seizures (see precautions, warnings). There have been isolated reports of movement disorders and rare cases of hyponatraemia. **Legal category:** POM. **Basic NHS cost:** 50mg tablet (PL 570308) Calendar pack of 28, £26.51; 100mg tablet (PL 570309) Calendar pack of 28, £39.77.

Further information on request.  
 Invicta™ Pharmaceuticals or  
 Richborough™ Pharmaceuticals  
 Divisions of Pfizer Limited, Sandwich, Kent.

